TY - JOUR
T1 - Genetic variations in tumor-suppressor miRNA-encoding genes and their target genes
T2 - focus on breast cancer development and possible therapeutic strategies
AU - Chhichholiya, Yogita
AU - Singh, Harsh Vikram
AU - Singh, Sandeep
AU - Munshi, Anjana
N1 - Publisher Copyright:
© 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2024/1
Y1 - 2024/1
N2 - MicroRNAs (miRNAs) negatively affect gene expression by binding to their specific mRNAs resulting in either mRNA destruction or translational repression. The aberrant expression of various miRNAs has been associated with a number of human cancer. Oncogenic or tumor-suppressor miRNAs regulate a variety of pathways involved in the development of breast cancer (BC), including cell proliferation, apoptosis, metastasis, cancer recurrence, and chemoresistance. Variations in miRNA-encoding genes and their target genes lead to dysregulated gene expression resulting in the development and progression of BC. The various therapeutic approaches to treat the disease include chemotherapy, radiation therapy, surgical removal, hormone therapy, chemotherapy, and targeted biological therapy. The purpose of the current review is to explore the genetic variations in tumor-suppressor miRNA-encoding genes and their target genes in association with the disease development and prognosis. The therapeutic interventions targeting the variants for better disease outcomes have also been discussed.
AB - MicroRNAs (miRNAs) negatively affect gene expression by binding to their specific mRNAs resulting in either mRNA destruction or translational repression. The aberrant expression of various miRNAs has been associated with a number of human cancer. Oncogenic or tumor-suppressor miRNAs regulate a variety of pathways involved in the development of breast cancer (BC), including cell proliferation, apoptosis, metastasis, cancer recurrence, and chemoresistance. Variations in miRNA-encoding genes and their target genes lead to dysregulated gene expression resulting in the development and progression of BC. The various therapeutic approaches to treat the disease include chemotherapy, radiation therapy, surgical removal, hormone therapy, chemotherapy, and targeted biological therapy. The purpose of the current review is to explore the genetic variations in tumor-suppressor miRNA-encoding genes and their target genes in association with the disease development and prognosis. The therapeutic interventions targeting the variants for better disease outcomes have also been discussed.
KW - CRISPR/Cas9
KW - miRNA
KW - RNAi
KW - SNP
KW - Target gene
UR - http://www.scopus.com/inward/record.url?scp=85153329361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153329361&partnerID=8YFLogxK
U2 - 10.1007/s12094-023-03176-8
DO - 10.1007/s12094-023-03176-8
M3 - Review article
C2 - 37093457
AN - SCOPUS:85153329361
SN - 1699-048X
VL - 26
SP - 1
EP - 15
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 1
ER -